Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of Dapagliflozin (DAPA) and Once-weekly Exenatide (EQW), Co-administered or Alone, DAPA/ Glucophage (DAPA/MET ER) and Phentermine/Topiramate (PHEN/TPM) ER on Metabolic Profiles and Body Composition in Obese PCOS Women

NCT02635386 is registered in ClinicalTrials.gov with Woman's as lead sponsor.

NCT NCT02635386
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02635386 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of Dapagliflozin (DAPA) and Once-weekly Exenatide (EQW), Co-administered or Alone, DAPA/ Glucophage (DAPA/MET ER) and Phentermine/Topiramate (PHEN/TPM) ER on Metabolic Profiles and Body Composition in Obese PCOS Women
Lead sponsor
Woman's
Phase
Phase 3
Overall status
Completed
Start date
March 22, 2016
Completion date
October 9, 2020
Enrollment
119 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, polycystic ovary syndrome